Rebecca Stanbrook is currently working as Global Head, Compliance and Regulatory Affairs Quality for Novartis Global Drug Development. She provides oversight across the GXPs to ensure compliance. She is very active in ISPE, sitting on the IP Steering Committee, the Special Interest Group Pharma 4.0 and the European Regulatory Committee. She is the MHRA HA liaison for TransCelerate.
Prior to joining Novartis Rebecca Stanbrook was Group Manager, Inspections (GLP/GCP/PV) at the Medicines and Healthcare products Regulatory Agency (MHRA). She joined the Agency in January 2003 as a GCP inspector. She was part of one of the teams which conducted the first statutory GCP inspections in the UK and played an active role in determining the statutory GCP inspection programme.
In July 2004 she was appointed Operations Manager of the Pharmacovigilance Inspectorate, co-ordinating the MHRA statutory Pharmacovigilance Inspection programme and also taking responsibility for the training strategy of the inspectorate. October of the same year saw her promotion to Senior GCP Inspector as well as continuing her Pharmacovigilance role.
Before joining the Agency Rebecca worked for over 11 years in the Pharmaceutical Industry in various roles, which included Clinical Trial Supplies, Clinical Quality Assurance Auditing and Training and Development. She holds an honours degree in Pharmacy.